Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, DeepCDR Collaborate on Antibody Library Design

NEW YORK – Twist Bioscience said on Thursday that it is collaborating with DeepCDR, a company applying deep learning algorithms to antibody discovery and optimization.

"DeepCDR offers a unique approach enabled by deep learning to generate large panels of fully human antibody sequences," Twist cofounder and CEO Emily Leproust said in a statement. "Utilizing these sequences, we've built multiple fully human naive synthetic antibody libraries — specifically, AI Hypermutated single-chain fragment variable (scFv) library and a new coronavirus-specific scFv library — to add to our ever-growing Library of Libraries."

Financial and other details of the deal were not disclosed.

Basel, Switzerland-based DeepCDR combines machine learning methods with a proprietary mammalian display platform to identify and select antibodies with high affinity and developability profiles.

Twist has used its synthetic antibody phage display libraries to ink multiple collaboration deals over the last few years.

Last month, it signed a deal with SomaLogic to identify antibodies against targets identified with the SomaScan proteomics platform. In April, Twist partnered with Pure Biologics, giving that firm access to select libraries, and last year, it licensed its libraries to Japan's Takeda Pharmaceutical.